1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
ASDReports Logo

Breast Cancer Therapeutics Market Expands in Asia-Pacific, According to a New Study on ASDReports


 
ASDReports.com
ASDReports.com
PRLog - Jun. 27, 2014 - AMSTERDAM, Netherlands -- Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts the new report.

According to the new report, now available on ASDReports, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

Saurabh Sharma, Analyst of the new report, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.

Sharma continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to the new study now available on ASDReports!


Notes for Editors:

If you are interested in a more detailed overview of this report, please go to : www.asdreports.com/ASDR-109564 or send an e-mail to sales@asdreports.com.

Media Contact
ASDReports.com
+31 (0)20 486 9620
stefan.koopman@asdreports.com

Photo:
http://www.prlog.org/12341029/1

--- End ---

Click to Share

Contact Email:
***@asdreports.com Email Verified
Source:ASDReports.com
City/Town:Amsterdam - Amsterdam - Netherlands
Industry:Marketing, Reports, Research
Tags:breast cancer, Cancer (Oncology), life sciences, diseases, Therapeutic Areas, market research, market report, ASDReports
Shortcut:prlog.org/12341029
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share